Latest Generate:Biomedicines News & Updates

See the latest news and media coverage for Generate:Biomedicines. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Generate:Biomedicines

Therapeutics company using machine learning for protein design

generatebiomedicines.com
Headquarters
Somerville, United States
Company type
Private company
Number of employees
300–500
Industry
Pharmaceuticals

Last updated

Latest news about Generate:Biomedicines

In short: Generate:Biomedicines went public with a $425 million IPO and advanced its AI-engineered asthma therapy, GB-0895, into Phase 3 trials.

Company announcements

Generate:Biomedicines

Generate:Biomedicines reports Q1 2026 financial results

Pipeline advances include Phase 3 for GB-0895, first patient dosing for GB-4362 in mid-2026, and GB-5267 collaboration with Roswell Park. Cash and marketable securities totaled $516.6 million as of March 31.

Generate:Biomedicines

Generate:Biomedicines completed its $400M IPO

The company sold 25M shares at $16 and is advancing a twice-yearly anti-TSLP antibody for severe asthma in Phase 3.

Unlock all announcements with a

Media coverage

Morningstar

Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update

SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advance Clinical trial sites activated for GB-4362 (MMAE neutralizer); first patient dosing is...

Unlock all articles with a

Never miss news about Generate:Biomedicines

Track Generate:Biomedicines and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Generate:Biomedicines competitors & trending companies

Browse news for competitors to Generate:Biomedicines and other trending companies.